Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCCC) (KEYNOTE-630)

Study ID
Merck MK-3475-630

NCT Number
(Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. Andrew Pecora


Merck Sharp & Dohme Corp.

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now